Comparison of Aripiprazole and Other Atypical Antipsychotics for Pediatric Bipolar Disorder: A Retrospective Chart Review of Efficacy and Tolerability
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: This study compared the efficacy and tolerability of aripiprazole with that of other atypical antipsychotics by examining patients with pediatric bipolar disorder (PBD) at a child and adolescent psychiatric clinic in a university hospital in Korea. Methods: We reviewed the medical records of 127 pediatric patients with bipolar disorder aged 4-18 years treated at Department of Child and Adolescent Psychiatric, Yonsei University Severance Hospital between January 2010 and October 2011 to collect demographic and clinical data. Using the Clinical Global Impression (CGI) scales, we evaluated levels of severity of and improvements in symptoms at the first, second, third, fourth, and fifth hospital visits. Results: The mean age of patients was 12.29±3.47 years. The sample included 91 (71.7%) male and 36 (28.3%) female patients. Aripiprazole was prescribed to 62 (48.8%) patients, risperidone to 52 (40.9%), quetiapine to 11 (8.7%), and paliperidone to two (1.6%). Patients treated with aripiprazole had lower CGI-Severity (CGI-S) scores than did patients treated with other atypical antipsychotics at the second and third visits. The CGI-Improvement (CGI-I) scores of patients treated with aripiprazole were lower at the second visit. Treatment with atypical antipsychotics was well tolerated, and no serious or fatal side effects were observed. Conclusion: The present retrospective chart review suggests that atypical antipsychotics may be effective and safe for the treatment of patients with PBD. In particular, treatment with aripiprazole may be more effective than treatment with other atypical antipsychotics in the early phase. These results should be verified in future multi-center controlled studies.
Abstract
Objective: This study compared the efficacy and tolerability of aripiprazole with that of other atypical antipsychotics by examining patients with pediatric bipolar disorder (PBD) at a child and adolescent psychiatric clinic in a university hospital in Korea. Methods: We reviewed the medical records of 127 pediatric patients with bipolar disorder aged 4-18 years treated at Department of Child and Adolescent Psychiatric, Yonsei University Severance Hospital between January 2010 and October 2011 to collect demographic and clinical data. Using the Clinical Global Impression (CGI) scales, we evaluated levels of severity of and improvements in symptoms at the first, second, third, fourth, and fifth hospital visits. Results: The mean age of patients was 12.29±3.47 years. The sample included 91 (71.7%) male and 36 (28.3%) female patients. Aripiprazole was prescribed to 62 (48.8%) patients, risperidone to 52 (40.9%), quetiapine to 11 (8.7%), and paliperidone to two (1.6%). Patients treated with aripiprazole had lower CGI-Severity (CGI-S) scores than did patients treated with other atypical antipsychotics at the second and third visits. The CGI-Improvement (CGI-I) scores of patients treated with aripiprazole were lower at the second visit. Treatment with atypical antipsychotics was well tolerated, and no serious or fatal side effects were observed. Conclusion: The present retrospective chart review suggests that atypical antipsychotics may be effective and safe for the treatment of patients with PBD. In particular, treatment with aripiprazole may be more effective than treatment with other atypical antipsychotics in the early phase. These results should be verified in future multi-center controlled studies.
참고문헌 (25)
- Biederman J, "Pediatric mania: a developmental subtype of bipolar disorder?", Biol Psychiatry, 48, pp.458~466 (2000)
- Post RM, "Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood", J Clin Psychiatry, 71, pp.864~872 (2010)
- Perlis RH, "STEP-BD Investigators. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD)", Biol Psychiatry, 55, pp.875~881 (2004)
- Leverich GS, "The poor prognosis of childhood-onset bipolar disorder", J Pediatr, 150, pp.485~490 (2007)
- McClellan J, "Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder", J Am Acad Child Adolesc Psychiatry, 46, pp.107~125 (2007)
- Smarty S, "Psychopharmacology of pediatric bipolar disorder: a review", Psychopharmacology (Berl), 191, pp.39~54 (2007)
- Pavuluri MN, "A pharmacotherapy algorithm for stabilization and maintenance of pediatric bipolar disorder", J Am Acad Child Adolesc Psychiatry, 43, pp.859~867 (2004)
- Correll CU, "Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents", J Clin Psychiatry, 69(Suppl 4), pp.26~36 (2008)
- Perlis RH, "Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials", J Clin Psychiatry, 67, pp.509~516 (2006)
- Joshi G, "A prospective open-label trial of quetiapine monotherapy in preschool and school age children with bipolar spectrum disorder", J Affect Disord, 136, pp.1143~1153 (2012)
- Barzman DH, "The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review", J Child Adolesc Psychopharmacol, 14, pp.593~600 (2004)
- Biederman J, "Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review", CNS Spectr, 10, pp.141~148 (2005)
- Findling RL, "Double-blind, randomized, placebo-controlled long-term maintenance study of aripiprazole in children with bipolar disorder", J Clin Psychiatry, 73, pp.57~63 (2012)
- Yoo HK, "An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders", J Clin Psychiatry, 68, pp.1088~1093 (2007)
- Kim JW, "The child behavior checklist together with the ADHD rating scale can diagnose ADHD in Korean communitybased samples", Can J Psychiatry, 50, pp.802~805 (2005)
- Conners CK, "Rating scales and checklists for child psychopharmacology", Psychopharmacol Bull, 21, pp.809~843 (1985)
- Geller B, "Child bipolar I disorder: prospective continuity with adult bipolar I disorder; characteristics of second and third episodes; predictors of 8-year outcome", Arch Gen Psychiatry, 65, pp.1125~1133 (2008)
- Duax JM, "Sex differences in pediatric bipolar disorder", J Clin Psychiatry, 68, pp.1565~1573 (2007)
- Escamilla I, "Pediatric bipolar disorder in a Spanish sample: results after 2.6years of follow-up", J Affect Disord, 132, pp.270~274 (2011)
- Kubacki A, "Male and female mania", Can J Psychiatry, 31, pp.70~72 (1986)
- Wilens TE, "Patterns of comorbidity and dysfunction in clinically referred preschool and school-age children with bipolar disorder", J Child Adolesc Psychopharmacol, 13, pp.495~505 (2003)
- Arnold LE, "Pediatric bipolar spectrum disorder and ADHD: comparison and comorbidity in the LAMS clinical sample", Bipolar Disord, 13, pp.509~521 (2011)
- Joshi G, "Response to second generation antipsychotics in youth with comorbid bipolar disorder and autism spectrum disorder", CNS Neurosci Ther, 18, pp.28~33 (2012)
- Zeni CP, "Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit", hyperactivity disorder: a randomized crossover trial, 2009, pp.19, 553~561
- Marder SR, "Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebocontrolled trials", Schizophr Res, 61, pp.123~136 (2003)